Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (October 2023)
27 slides from Revelation Biosciences's investor presentation, Oct 12, 2023
Slide 1: Corporate Presentation October 2023
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Therapeutic Development Pipeline
Program Number (Indication) 2023 2024 2025 REVTx-100 (Gemini for the prevention of hospital acquired infection) REVTx-300 (Gemini for the prevention of AKI/treatment of CKD) Therapeutic Development Pipeline Revelation has a pipeline of potential high-value products based on the activity of Gemini Ge
Slide 4: PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications
PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications 1. Zwirner, N. and Ziblat, A. 2017 doi: 10.3389/fimmu.2017.00025 2. Ismaeli, J. et. al. 2022 doi: 10.4049/jimmunol.168.2.926 3. Hernandez, A. et. al. 2019 DOI: 10.1097/CCM.0000000000003967 4. Revelation Data Gemini administrati
Slide 5: REVTx-100 Program: Gemini for the Prevention of Hospital Acquired Infection
REVTx-100 Program Gemini for the Prevention of Hospital Acquired Infection
Slide 6: REVTx-100 Program Highlights
REVTx-100 Program Highlights Scientific Rationale 1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov Gemini administration potentially: Initiates immune cell mobilization and production, priming the body for pathogen clearance Downregulates the pro-inflammatory response, reducing cellular dam
Slide 7: Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection
Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Study Design: Mice were pre-treated (24 and 48 hours) with vehicle
Slide 8: Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated improved pathogen c
Slide 9: Healthy Animal Study: Gemini Administration Induces White Blood Cell Mobilization
Study Design: Dogs received a single dose of vehicle Gemini and blood samples were collected at various time-points up to 24 hours post dose for analysis (n=3–10 per group) Healthy Animal Study: Gemini Administration Induces White Blood Cell Mobilization Gemini administration results in white blood
Slide 10: Healthy Animal Study: Gemini Administration Induces Key Cytokines
Healthy Animal Study: Gemini Administration Induces Key Cytokines Gemini administration resulted in a dose dependent increase in cytokines following a single dose IL-10 is characterized as an anti-inflammatory cytokine leading to the ultimate resolution of inflammation. NGAL (data not shown) sequest
Slide 11: Phase 1 Clinical Study
Phase 1 Clinical Study1 8 subjects per cohort randomized 1:4 placebo vs drug Study start anticipated in Q4 2023 Title: A Phase 1, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose Followed by Multiple Ascending Dose Study in Healthy Volunteers Part 1 Single ascending doses of Gemin
Slide 12: Total US Addressable Market for REVTx-100 Program is over 6.3M Annual Procedures
Total US Addressable Market for REVTx-100 Program is over 6.3M Annual Procedures Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014 Claudia A. Steiner, M.D., M.P.H., Zeynal Karaca, Ph.D., Brian J. Moore, Ph.D., Melina C. Imshaug, M.P.H., and Gary Pickens, Ph.D. Our
Slide 13: The Impact of Surgical-Site Infections (SSI)
The Impact of Surgical-Site Infections (SSI) DOI:10.1001/jamasurg DOI:10.1086/676022 DOI: 10.1016/j.jamcollsurg.2016.10.029 ~€11bn represents the midpoint of the range discussed in WHO Global guidelines on the prevention of surgical site infection. Nov 2016 DOI: 10.1086/501572 Up to 30% Estimated SS
Slide 14: REVTx-300 Program: Gemini for the Prevention of Acute Kidney Injury and Chronic Kidney Disease
REVTx-300 Program Gemini For the Prevention of Acute Kidney Injury and Chronic Kidney Disease
Slide 15: REVTx-300 Program Highlights
Gemini preconditions the innate immune system through a process of trained immunity, comprising redirection and attenuation of the innate immune system’s response to external stress (infection, trauma, etc.) Allows for rapid response to external stress Downregulates the pro-inflammatory response, re
Slide 16: PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model 1 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice pretreated with
Slide 17: PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model1 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice were pretreated wi
Slide 18: Gemini Treatment Reduces Fibrosis in Acute and Chronic Kidney Model
Gemini Treatment Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats) Composite data represents the average of 3 anatomically distinct depths (10 images / depth / rat / group = ~60-65% of renal cortical area) Renal cortical fibrosis, expressed as Collagen Volume Fraction (CVF; via quanti
Slide 19: Gemini Antifibrotic Effects Likely Mediated by Validated Target Cytokines
Gemini Antifibrotic Effects Likely Mediated by Validated Target Cytokines TGF-β is pro-fibrotic and is directly linked to the propagation of fibrosis1,2,3,4 IL-10 is a key driver for the reduction and resolution of inflammation NGAL is an important defense for preventing excessive oxidative damage r
Slide 20: Healthy Animal Study: Effect of Second Dose on Cytokine Response
Healthy Animal Study: Effect of Second Dose on Cytokine Response Administration of two doses of Gemini results in an initial increase in both inflammatory and protective cytokines following a first dose and an attenuated pro-inflammatory response following a second dose at 24 hours (e.g. a smaller i
Slide 21: Phase 1 Clinical Study
Phase 1 Clinical Study1 8 subjects per cohort randomized 1:4 placebo vs drug Study start anticipated in Q4 2023 Title: A Phase 1, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose Followed by Multiple Ascending Dose Study in Healthy Volunteers Part 1 Single ascending doses of Gemin
Slide 22: Total US Addressable Market for REVTx-300 Program
Total US Addressable Market for REVTx-300 Program is over 42M Annual Potential Patients Our initial strategy will be to seek approval for prevention of AKI following surgery Initial clinical studies will enroll patients undergoing cardiac surgery Conservatively, if we treat 20% of the cardiac surger
Slide 23: AKI Epidemiology
AKI Epidemiology In the US, 1% of all hospital admissions have AKI on admission1 During hospitalization, the approximate incidence rate of acute kidney injury is 2 to 5% and it develops in up to 67% of patients admitted in the intensive care unit1 AKI is an important contributor to increased hospita
Slide 24: AKI as a Result of Cardiac Surgery
AKI as a Result of Cardiac Surgery DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084 Up to 31% Of patients undergoing cardiac surgery with no prior CKD develop post operative AKI3 50% Death rate of patients that develop post operative AKI2 $42.6k Average
Slide 25: Financial Overview
> REVELATION Financial Overview ~ BAOESI@IIEINIGIESS
Slide 26: Cap Table and Management Holdings
Management holdings Percent George Tidmarsh, M.D., Ph.D. (Chairman) 2.0% All other management 0.8% Total management 2.8% Cap Table Shares Common Stock Outstanding 6,297,303 Class C common stock warrants w/$5.36 exercise 487,160 Public Warrants w/$402.50 exercise (REVBW) 300,332 Warrants w/$24.20 wei
Slide 27: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (October 2023) on 6ix